SUMMARY. Purified radiolabeled rabbit Hageman factor, prekallikrein, and high molecular weight kininogen were used to examine Hageman factor system molecular dynamics after the intravenous injection of heparin-like dextran sulfate polymer in the rabbit. Hageman factor system proteins rapidly disappeared from the circulation following dextran sulfate injection, as measured by radial immunodiffusion, by kaolin-releasable kinin formation, and by measuring circulating levels of radiolabeled Hageman factor, prekallikrein, and high molecular weight kininogen.
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Hageman factor was distributed mainly to lung, liver, and spleen following dextran sulfate injection. Proteolysis of circualting 125 I-Hageman factor occurred at a site within a disulfide loop into fragments of 50,000 and 30,000 molecular weight. Proteolysis of 125 I-prekallikrein also occurred with visualization of a 50,000 molecular weight fragment. Although extensive proteolysis of l; "I-high molecular weight kininogen was observed, the cleavage fragments were not the same as those generated during contact activation in vitro. The major fragment of high molecular weight kininogen observed in vivo was at 80,000 molecular weight, in contrast to the 65,000 molecular weight fragment generated by kallikrein in vitro. These results indicate that high molecular weight kininogen can undergo proteolysis in vivo into fragments not known to be associated with kinin release. (Circ Res 58: 595-604, 1986) INTRAVENOUS injection of ellagic acid into dogs produces hypotension and a "hypercoagulable state" which has been attributed to Hageman factor system activation (Botti and Ratnoff, 1964) . In the present study, heparin-like sulfated dextran was injected intravenously into rabbits in an attempt to measure the effect of activating the Hageman factor system in vivo. The Hageman factor system is known to be activated by dextran sulfate in vitro (Kluft, 1978) . Hageman factor system activation would be expected to generate bradykinin in the vascular compartment and, therefore, to be associated with hypotension (Cochrane and Griffin, 1982; Kaplan, 1983) . The heparin-like effect of dextran sulfate would be expected to inhibit procoagulant events (Walton, 1953 (Walton, , 1954 . After dextran sulfate injection into rabbits, hypotension did indeed occur (30-45% fall in mean arterial pressure), together with bradycardia, wheezing, bowel peristalsis, micturition, and defecation (Wiggins et al., 1985) . However, the hypotension observed was shown to be due to platelet release of serotonin and to be independent of the Hageman factor system. This latter fact was demonstrated by the persistence of dextran sulfate-induced hypotension in rabbits depleted of circulating Hageman factor by infusion of goat antirabbit Hageman factor immunoglobulin G (IgG), and, also, by the failure of the angiotensin-converting enzyme, SQ20881, to potentiate the hypotension observed (Wiggins et al., 1985) . Because of these unexpected results, a detailed analysis of Hageman factor system protein turnover and proteolysis in the rabbit following intravenous injection of dextran sulfate was undertaken.
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where one clotting unit is the amount of activity present in 1 ml of normal citrated rabbit plasma (different from 1 unit of human HF). All HF assays were performed using human HF-deficient plasma.
Prekallikrein Purification
Prekallikrein was purified from citrated rabbit plasma as previously described (Wiggins et al., 1981) . Briefly, a goat antirabbit prekallikrein Sepharose 4B immunoaffinity column was used to bind the prekallikrein in rabbit plasma. After extensive washing, the prekallikrein was eluted with 5 M guanidine. The guanidine-containing fractions were dialyzed and passed over an SP-Sephadex column at pH 5.3. The prekallikrein was eluted with a salt gradient. The prekallikrein-containing fractions were pooled, dialyzed against 0.1 M phosphate buffer, pH 7.5, containing 1 M NaCl, and passed over a concanavalin-ASepharose column. The prekallikrein was eluted with ct-D-methyl glucoside. The prekallikrein so purified was a homogeneous single protein band at 83,000 molecular weight as judged by SDS-polyacrylamide gel electrophoresis under reducing and nonreducing conditions.
High Molecular Weight Kininogen Purification
High molecular weight kininogen was purified from citrated rabbit plasma as previously described (Wiggins et al., 1981) . Briefly, a goat antirabbit kininogen Sepharose 4B column was used to bind the protein in citrated rabbit plasma. After the column was washed extensively, the high molecular weight kininogen was eluted with 4 M guanidine. The guanidine-containing fractions were pooled, dialyzed against 0.4 M Tris buffer, pH 8.2, and passed over a DEAE-Sephadex A50 column. A salt gradient was used to elute the kininogens from the column so that low and high molecular weight kininogens were separately eluted in the proximal and distal parts of the major protein peak, respectively. The high molecular weight kininogen-containing fractions were pooled, dialyzed against 0.1 M acetate buffer, pH 5.3, and passed over an SP-Sephadex column. The high molecular weight kininogen was eluted with a salt gradient. The material so eluted was predominently (about 85%) a single protein band with an apparent molecular weight of 105,000 under reducing and nonreducing conditions. Under reducing conditions, minor containment proteins or fragments appeared at 90,000 and 65,000 molecular weight.
Kallikrein Generation
Kallikrein was generated by incubating prekallikrein with two-chain 80,000 molecular weight-activated Hageman factor (a-HF.) which had been purified as previously described (Wiggins, 1983) . Prekallikrein (220 jig, 1 ml) was incubated with a-HF n (50 fi\, 10 jig) in the presence of 10 M' 2 M Tris, pH 8.0, for 60 minutes at 37°C. The enzymatic activity was measured using the tripeptide substrate N-benzoyl-L-pro-L-Phe-L-argenine-pNC>2 analide, (Vega Biochemicals). The Kc of this material varied between 150 and 200/min, using a molar extension coefficient of 10,000/m per cm at 405 nm. These values are similar to those previously described for rabbit kallikrein (Ulevitch et al., 1980) .
Radial Immunodiffusion Assays
These assays were performed according to the method of Mancini (1965) . The antisera used were raised against the purified protein in goats, and gave single precipitin Circulation Research/Vol. 58, No. 4, April 1986 lines against normal citrated rabbit plasma when tested by immunodiffusion analysis.
Trypsin and Kaolin-releasable Kinin Measurements by Bioassay
This was performed by a modification of the method reported by Uchida and Katori (1979) . To measure total kininogen, citrated rabbit plasma (200 fi\) was acidified to pH 2 by the addition of 1.8 ml 0.03 M HC1. After incubation at 37°C, the mixture was neutralized by the addition of 0.05 ml of 1 M NaOH. Trypsin (200 ^g) in 200 nl of 40 rriM Tris buffer, pH 7.8, was then added and incubated for 30 minutes at 37°C. Ethanol (7 ml) was then added to the mixture. After centrifugation, the supernatant was evaporated to dryness and, after reconstitution in buffer, was assayed as described below.
Kinin release from high molecular weight kininogen was measured using kaolin to activate the HF system. Citrated plasma (200 /il) was diluted with 1.8 ml 60 rrtM Tris buffer, pH 7.4, and mixed with O-phenanthroline at a final concentration of 2 mg/ml plasma. To this mixture was added kaolin (10 mg/ml plasma). The mixture then was incubated for 30 minutes at 37°C. Incubation was stopped by boiling the mixture for 4 minutes. The mixture then was centrifuged (10,000 g) for 5 minutes, and the supernatant was stored at -70°C for assay.
The bioassay system used was an estrogen-sensitized rat uterus, as previously described (Wiggins et al., 1980) . Briefly, female Brown Norway rats were injected with diethylstilbestrol (100 ^g in mineral oil) 18 hours prior to assay. The uterus was removed, and a single horn was used in a constant temperature Schultz-Dale apparatus for kinin assay. Synthetic bradykinin (Sandoz Inc.) was used as a standard. The assay was sensitive to 1 ng bradykinin. The results were quantified by measuring the time from stimulus to contraction. A linear relationship was found between the log of the time between stimulus and contraction and the dose of bradykinin. Results were expressed as bradykinin equivalents in nanograms. Recoveries of bradykinin added back to O-phenanthrolinerreated plasma were 66-80%.
Radiolabeling
Purified proteins were radiolabeled by the chloramine-T method (McConahey and Dixon, 1966) . The specific activity of all radiolabeled proteins was about 1 fiCi/jig. All radiolabeled proteins were assayed by adding the label to citrated rabbit plasma and then incubating the plasma with kaolin (final concentration, 5 mg kaolin/ml plasma) for 20 minutes at 37°C. The radioactive profiles of the protein were then analyzed by SDS-polyacrylamide gel electrophoresis under reducing and nonreducing conditions. In all cases prior to incubation with kaolin, most of the radioactivity (more than 90% for 125 I-HF and I25 Iprekallikrein and more than 74% in the case of 131 I-high molecular weight kininogen) was in a single major peak corresponding to the molecular weight of the native protein, as can be seen in the gel profiles in Figures 4 and 7) . After incubation with kaolin and analysis under reducing conditions, the radiolabeled proteins underwent proteolysis into fragments associated with activation. In the case of I25 I-Hageman factor, both the 50,000 and 30,000 molecular weight fragments were labeled, although most of the radioactivity was in the light chain. In the case of 12J Iprekallikrein, only the 50,000 molecular weight heavy chain was consistently labeled. In the case of Wiggins/Kininogen Proteolysis in Vivo molecular weight kininogen, only the 65,000 molecular weight heavy chain was labeled.
Animal Studies
All studies were performed on 2-to 2.5-kg rabbits anesthetized with sodium pentobarbitone (10-15 mg/kg). The anesthetized rabbits were placed supine on boards, and femoral arterial and venous catheters (Intramedic PE 50 tubing) were introduced under local anesthetic. Urinary catheters were also placed so that radioactive urine could be collected safely. Systemic arterial pressure was measured with a Statham pressure transducer (P37B) and a Stratham SP1400 blood pressure monitor. Radiolabeled proteins, either as the pure protein or as citrated plasma (5-8 ml) from the rabbits used to screen the label, as described below, was injected into each rabbit via the marginal ear vein. Labeled proteins were allowed to equilibrate for 60-180 minutes. Venous blood samples (1.8 ml) were collected at various time intervals (as described in the Results) into 200 nl of 3.8% sodium citrate in a plastic tube. After mixing, the tubes were immediately centrifuged at 10,000 g for 5 minutes. The plasma was removed with a plastic pipette and aliquotted into plastic tubes for storage at -70°C for further analysis. Dextran sulfate (500,000 molecular weight, Pharmacia) dissolved in 0.15 M NaCl (20 mg/ml) was injected into a marginal ear vein (20 mg/kg) over a 10-second period. Blood pressure was recorded continuously. For the I25 1-HF distribution studies, rabbits were killed 5 minutes and 20 minutes after dextran sulfate injection. Three minutes before sacrifice, a blood marker ('"I-albumin, 40 ^Ci) was injected via the marginal ear vein catheter. Rabbits were killed by intravenous injection of sodium pentobarbitone (100 mg). Before the heart stopped beating, a rapid autopsy was performed where the following tissues were removed: blood, liver, spleen, kidney, heart, lung, stomach, small bowel, large bowel, psoas muscle, abdominal fat, skin. The tissues for subsequent polyacrylamide gel electrophoresis SDS-PAGE analysis were immediately placed on a slab of dry ice to freeze and then into a precooled plastic tube prior to freezing at -70°. Tissues and organs to be used for calculating organ distribution of 125 I-HF were placed in a plastic dish. The total organ weight (for heart, lung, liver, kidney, and spleen) was measured. Approximately lg of tissue was then cut from each organ/tissue, weighed accurately on a Mettler balance, and the radioactivity in that piece of tissue counted on a 7-counter. Cross-over ( I in each tissue in excess of that calculated to be present from the blood in that tissue was then calculated. For the purpose of calculating the amount of Hageman factor bound in each tissue, it was assumed that each rabbit had a circulating plasma HF concentration of 12 Mg/ml prior to injection of dextran sulfate (this value was previously measured by radial immunodiffusion in a pool of rabbit plasma made from 20 rabbits, using as a standard purified rabbit Hageman factor whose protein concentration had been measured by amino acid analysis). It was assumed that the trichloroacetic acid (TCA)-precipitable 125 I in plasma immediately before injection of dextran sulfate in each rabbit was equivalent to 12 Mg/ml HF. Using this 597 value, the amount of HF bound in each organ/tissue at the time of sacrifice in control and dextran sulfate-treated animals was calculated and expressed as Mg HF/g tissue (Table 1) .
Distribution studies require that nonspecific removal of labeled molecules which have been damaged by purification, storage, or radiolabeling procedures be minimized. Therefore, I-HF and 131 I-albumin were 'screened' by allowing these labeled proteins to circulate for 3 hours in rabbits prior to their use for the distribution study, so that any molecules that would have been rapidly removed from the circulation are not injected into the experimental animals I-albumin) were each injected intravenously into a rabbit in two separate experiments. The rabbit had previously been anesthetized with sodium pentobarbitone (10-15 mg/kg) and had had a femoral arterial catheter and a urinary catheter placed to collect radioactive blood and urine, respectively. After 3 hours, 90 ml of blood were collected into 9 ml of 3.8% sodium citrate in plastic tubes. The blood was centrifuged for 20 minutes at 3,000 g and then the plasma was again centrifuged at 15,000 g for 1 hour to remove all cells. The plasma was then frozen at -70°C prior to use for distribution studies. The radioactivity in plasma varied between 0.3 and 0.8 /iCi/ml in different experiments.
For the study of proteolysis of 
SDS-Polyacrylamide Gel Analysis of Labeled Protein in Plasma and Tissue
To maximize the amount of radioactivity available for analysis, large (1.5 cm X 10 cm) 10% polyacrylamide gels were used. These gels give good resolution with as much as 5 mg of protein loaded. A Laemmli buffer system was used (Laemmli, 1970) . The gels were run in a Bio-Rad electrophoretic system (Bio-Rad Laboratories). One hundred microliters of glycerol (3%) and bromophenol blue were added to each sample before layering on the top of the stacking gel. Gels were run at 2 mA/gel overnight. The completed gel, including stacking gel, was removed from the glass tube, roled up in a piece of parafilm, and frozen at -30°C. The frozen gel was allowed to thaw slightly, and then the stacking gel was sliced off (slice 1). The rest of the gel was sliced into 2-mm slices which were each put in a glass tube. All slices were counted for radioactivity for 5 min/slice, in an automatic 7-counter. Each slice was then corrected for I-albumin was in the nonpelleted material. The amount of radioactivity from tissues loaded onto each gel varied between 5,000 and 22,000 counts/min. Radioactivity profiles could be obtained with as little as 5,000 counts/min loaded onto each gelPlasma samples (50 n\) were boiled with 50 fi\ of 10% SDS containing 8 M urea with and without 5% /3-mercaptoethanol. As positive controls to act as internal standards for activation fragments, plasma samples obtained prior to injection of dextran sulfate were preincubated with kaolin (5 mg/ml) or dextran sulfate (500 jig/ml) for 20 minutes at 37°C and 4°C, respectively, prior to analysis by SDS-polyacrylamide gel electrophoresis.
Trichloroacetic Acid Precipitation of Radioactivity in Plasma
Plasma (1 ml) was mixed with 30% trichloroacetic acid (1 ml) in a plastic tube and left on ice for 20 minute. The tube was then centrifuged at 5,000 g for 20 minutes at 4°C. The supernatant was again discarded. The pellet was resuspended in 15% trichloroacetic acid, and then recentrifuged as described above. The supernatant was again discarded. The radioactivity in the pellet was counted in a 7-counter. For the turnover experiments, the data for each animal were calculated as the percent change from the first plasma sample.
Statistics
The data in Table 1 were compared using the f-test and were expressed as the mean plus or minuse the standard error of the mean. For all other diagrams, data are expressed as the mean ± the standard error of the mean.
Results

Levels of Circulating Proteins
Radial immunodiffusion analysis was used to measure the amounts of HF, prekallikrein, Factor XL, C 3 , plasminogen, fibrinogen, and IgG in plasma after intravenous injection of dextran sulfate. The results are shown in Figure 1 . Immediately after injection of dextran sulfate, a decrease in antigen levels of Hageman factor system proteins (HF, prekallikrein, and Factor XI) was observed, while not much change occurred in C 3 , plasminogen, fibrinogen, or IgG.
Measurement of Trypsin and Kaolin-releasable Kinin
An estrogen-sensitized rat uterus bioassay was used to measure kinin release from plasma obtained at various times after injection of dextran sulfate. Total releasable kinin was measured by incubating trypsin with plasma (see Methods). Hageman factor system-dependent kinin release was measured by preincubating plasma samples with kaolin (see Methods). The results are shown in Figure 2 . Immediately after injection of dextran sulfate, kaolinreleasable bradykinin became undetectable. Trypsin-releasable kinin fell by about 15%, although this change was not statistically significant. Since the kaolin assay requires an intact Hageman factor system for kinin release, the failure to measure kinin following incubation of plasma with kaolin could be due to decrease or inactivated Hageman factor, prekallikrein, or high molecular weight kininogen, or a combination of the above.
Turnover and Distribution of 12S I-HF after Dextran Sulfate Injection
Circulating 125 I-HF was measured in two groups of three rabbits. One group received dextran sulfate (20 mg/kg), intravenously. As shown in Figure 3 , there was an immediate fall in circulating I-HF level by 28% 3 minutes after dextran sulfate injection. Analysis of the circulating 12! I-HF by SDSpolyacrylamide gel electrophoresis is shown in Figure 4 . Before injection of dextran sulfate, a single peak of radioactivity at 80,000 molecular weight was present under both reducing and nonreducing (Fig. 4) . After dextran sulfate injection, peaks of radioactivity at approximately 30,000 and 50,000 molecular weight were present under reducing conditions similar to those seen when the control plasma (obtained prior to injection of dextran sulfate) was incubated with dextran sulfate in vitro (Fig. 4) . A comparison of the profile obtained under reducing and nonreducing conditions shows that, 5 minutes after dextran sulfate injection, more proteolysis was seen in the presence of reducing agent. This result is similar to that of the positive control (dextran sulfate incubated with control plasma in vitro), and indicates that proteolysis of I-HF occurred at a site within a disulfide loop. This cleavage site is the one associated with activation of the HF molecule (Cochrane and Griffin, 1982; Dunn and Kaplan, 1982) . The additional high molecular weight peak of radioactivity seen when dextran sulfate was incubated with plasma in vitro probably represents an enzyme-inhibitor complex, which may be rapidly removed from the circulation in vivo.
R E L E A S A B L E B R A O Y K I N I N E Q U I V A L E N T S , o _
I-Hageman Factor Tissue Distribution after Dextran Sulfate Injection
Two distribution studies were performed to determine where the 125 I-HF had gone, following dextran sulfate injection. The tissue distribution of 125 I-HF was studied 5 and 20 minutes after dextran sulfate injection. For these studies, 131 I-rabbit albumin was injected 3 minutes before sacrifice to act as a blood marker. Two groups of three rabbits were used for each study. One group received dextran sulfate, while the other acted as a control. The results are snown in for measurement of circulating HF in pooled rabbit plasma as described in the Methods section). The results from these distribution studies show that increased 125 I is found in several organs, particularly lung, after injection of dextran sulfate.
Analysis of the 125 I-HF in tissues by SDS-polyacrylamide gel electrophoresis in four organs obtained 20 minutes after dextran sulfate injection is shown in Figure 5 . The radioactivity profiles show that 125 I-HF in organs had undergone proteolysis following dextran sulfate injection. This was particularly seen in lung where a 28,000 molecular weight fragment was seen under both nonreducing and reducing conditions. In liver and spleen, cleavage of 125 I-HF into a 28,000 molecular weight fragment was present in dextran sulfate-treated rabbits. A higher molecular weight peak, which might be an enzyme-inhibitor complex, was also seen in spleen. Most of the radioactivity in kidney was present as low molecular weight fragments which migrated with the dye front of the SDS gel.
Turnover and Proteolysis of
-Prekallikrein
When dextran sulfate was injected into rabbits with circulating 125 I-prekallikrein, there was a rapid disappearance of about 22% of 125 I-prekallikrein from the circulation (Fig. 6, top panel) . When plasma obtained at various times after injection of dextran sulfate was analyzed by SDS-polyacrylamide gel electrophoresis in the presence of reducing agent, proteolysis of the 125 I-prekallikrein into a major peak at about 50,000 molecular weight was seen (Fig. 7) . The smaller 30,000 molecular weight fragment was not seen, because no label was bound to this part of the molecule (see Methods). The extent of proteolysis in relation to time after injection of dextran sulfate is shown in Figure 6 , bottom panel. system occurred after intravenous injection of dextran sulfate.
Turnover and Proteolysis of 131
I-High Molecular Weight Kininogen
Turnover and proteolysis of circulating 131 I-high molecular weight kininogen was examined in the same animals as those described above containing 125 I-prekallikrein. After intravenous injection of dextran sulfate (20 mg/kg)/ there was a rapid fall in the level of 131 I-high molecular weight kininogen similar to that seen for 125 !-prekallikrein (Fig. 6, to panel) . When proteolysis was examined and expressed as proportion of molecules remaining at 105,000 molecular weight, as much as 53% of molecules had undergone proteolysis by 5 minutes. However, as shown in Figure 7 , the cleavage products were different from those seen when contact activation occurs. The major fragment seen after activation by kallikrein was at approximately 65,000 molecular weight. This is illustrated in vitro on the righthand side of Figure 7 , where the 131 I-high molecular weight kininogen (and 125 I-prekallikrein) was incubated either with kallikrein alone or when kallikrein was added to the plasma prepared from blood removed immediately prior to dextran sulfate injection (and which therefore contained both 131 I-high molecular weight kininogen and 125 I-prekallikrein). In both cases, the major fragment of I-high molecular weight kininogen seen was at about 65,000 molecular weight (between native prekallikrein at 80,000 dalton and the 50,000 molecular weight cleavage fragment of prekallikrein). In contrast, the major cleavage fragment of 131 I-high molecular weight seen in vivo coincided with the native prekallikrein peak at about 80,000 dalton. Only a small peak of radioactivity was seen at 65,000 molecular weight. This result was reproducible in the six rabbits studied. Nonreduced gels were not analyzed in this experiment. Since only the heavy chain portion of the high molecular weight kininogen molecule was labeled (see cleavage patterns on the right side of Fig. 7) , and assuming that the label was distributed at several sites on the heavy chain, we can conclude that cleavage of most of the 131 I-high molecular weight kininogen molecules probably occurred within the light chain region of the molecule. Furthermore, since kinin release is associated with proteolysis into the 65,000 and 40,000 molecular weight fragments of high molecular weight kininogen, it seems likely that kinin release was not associated with the cleavage resulting in production of the 80,000 molecular weight fragment.
Discussion
The surprising finding in this study was that the 131 I-high molecular weight kininogen molecules had undergone proteolysis to form an 80,000 molecular weight fragment. There is no doubt that this did in fact occur, because the 125 I-prekallikrein, which was circulating in the same animals, provided an internal marker in the SDS-polyacrylamide gels. The question for discussion is therefore how one interprets this result.
Plasma kallikrein normally cleaves high molecular weight kininogen into fragments of 65,000 and 45,000 dalton (Thompson et al., 1978; Kerbiriou and Griffin, 1979) . Cleavage at this site is associated with bradykinin release. The 80,000 molecular weight fragmentation is not consistent with bradykinin release. We can therefore conclude that if all the kininogen molecules were cleaved at this site, then bradykinin-mediated events, such as hypotension, would not be expected. In fact acute hypotension was observed following dextran sulfate injection, but the hypotension was shown to be independent of Hageman factor, and was not potentiated by the angiotensin-converting enzyme inhibitor, SQ20881. The dextran sulfate-mediated acute hypotension was shown to be mediated by platelet serotonin release via an autonomic reflex (Wiggins et al.,1985) . Therefore, the finding that the kininogen molecules were cleaved at a non-kallikrein site fits in with the observation that the hypotension was not kinin-related.
Proteolysis of the kininogen molecule at a nonkallikrein cleavage site presumably occurred as a result of enzymatic activity generated either in plasma or from cells activated by dextran sulfate injection. Dextran sulfate has previously been shown to activate the alternative complement pathway (Burger et al., 1975) , and in this model, complement-dependent neutropenia was observed (Wiggins et al., 1985) . Factor XIa has also recently been reported to cleave the kininogen molecule at different sites (Scott et al., 1983) . The most likely candidates seem to be enzymes released from activated cells. One possible candidate is the tryptase from basophil granules previously shown to be able to cleave human high molecular weight kininogen in vitro (Maier et al., 1983 ). However, the major cleavage fragment found with this enzyme was at 66,000 dalton under reducing conditions, which is different from the 80,000 molecular weight fragment observed in this study. Further support for cellular activation is provided by the previous finding that aggregated platelets and neutrophils, as well as degranulated basophils and eosinophils, were present within lung capillaries following dextran sulfate injection (Wiggins et al., 1985) . These or other cells might have released enzymes capable of cleaving circulating 125 I-high molecular weight kininogen.
When circulating radiolabeled Hageman factor and prekallikrein were examined, it was found that they had undergone proteolysis at sites consistent with activation of these molecules (Mandle and Kaplan, 1977; Ulevitch et al., 1980; Dunn and Kaplan, 1982; Cochrane and Griffin, 1928) . Thus, 125 I-Hageman factor was cleaved into 50,000 and 28,000 molecular weight fragments mainly at a site within a disulfide loop, and 125 I-prekallikrein was cleaved to form a 50,000 molecular weight fragment. It should be clearly noted that, whereas zymogens are often activated by limited proteolysis, the demonstration of proteolytic cleavage does not necessarily mean that the zymogen has been activated. Nevertheless, these cleavage sites are compatible with activation of these molecules by dextran sulfate, a substance well known to be capable of activating
